78D.F ALZINOVA AB

Healthcare Biotechnology Frankfurt Exchange
0.0001 EUR
Close of Nov 11, 2026
0.0001 0.1450
Market cap
EUR 31.6K
P/E
-
P/B
0.01x
ROE
-14.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 78D.F undervalued?

Graham number

The Graham number of ALZINOVA AB cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

ALZINOVA AB fundamental analysis

No fundamental analysis for ALZINOVA AB yet.

ALZINOVA AB stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About ALZINOVA AB

Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. The company's lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b clinical trial. It also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzhe…

Full company profile